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Recent breast cancer treatment studies conducted in large urban settings have reported racial 
disparities in the appropriate use of adjuvant chemotherapy. This article presents the first focused 
evaluation of black–white differences in receipt and completion of chemotherapy for breast cancer 
in a primarily rural region of the United States. We performed chart abstraction on initial therapy 
received by 868 women diagnosed with Stages I, IIA, IIB, or IIIA breast cancer in 2001–2003 in 
southwest Georgia (SWGA). For chemotherapy, information collected included treatment plan, 
dates of delivery, concordance between therapy planned and received, and date and reasons for 
end of treatment. The patient’s age at diagnosis, race, marital status, insurance coverage, hormone 
receptor status, comorbidities, socioeconomic status, urban/rural status, treatment site, and 
distance to the site were also collected. Following univariate analyses, we used multivariable 
logistic regression modeling to examine the impact of race on the likelihood of (1) receiving 
chemotherapy and (2) completing planned chemotherapy. For patients terminating chemotherapy 
prematurely, the reasons were documented. The results showed that the unadjusted black–white 
difference in receipt of chemotherapy (48.3 vs. 36.0%) was significant, but in the multivariable 
analysis the black – white odds ratio (OR = 1.18) was not. While the unadjusted black–white 
difference (92.0 vs. 87.8%) in completing chemotherapy was not significant, in multi-variable 
models black race was positively associated with completing care (p ranging from 0.032 to 0.087 
and OR, correspondingly, from 2.16 to 2.64). The impact of race on completing chemotherapy 
was influenced by marital status, with a significant black–white difference for patients not married 
(OR = 4.67), but no difference for those married (OR = 1.06). We find compelling racial 
differences in this largely rural region—with black breast cancer patients receiving or completing 
chemotherapy at rates that equal or exceed white patients. Further investigation is warranted, both 
in SWGA and in other rural regions.
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Introduction
The effectiveness of adjuvant chemotherapy in reducing disease recurrence and improving 
overall and disease- free survival in early stage breast cancer has been demonstrated over 
time in multiple-randomized trials [1–5] and recent population-based studies [6, 7]. For 
maximum impact, the planned course of treatment should be delivered until completion, 
unless there are clinically sound reasons for stopping or delaying therapy [1, 3].
Previous studies have found that incomplete treatment with adjuvant chemotherapy in breast 
cancer is associated with poorer survival and, in addition, a higher percentage of black 
women received less than expected treatment compared with whites [8–10]. While 
compelling, these findings must be interpreted through the prism of the patient populations 
studied, as well as the information available for defining and evaluating cancer care receipt 
and completion. Relevant investigations to date include clinical trials [9], observational 
studies using linked registry-administrative data files [6, 7], at least one statewide analysis 
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[11], and studies of specific urban–suburban populations [8, 10–12]. With rare exception 
[13], little attention has been directed to non-metropolitan areas. Consequently, our current 
knowledge is limited regarding the delivery of chemotherapy for breast cancer in rural 
America.
Equally important are the methods that investigators have adopted for defining and 
evaluating chemotherapy completion. Whether using data from clinical trials [9], medical 
records [8], or linked registry-administrative data [14], studies have typically needed to 
employ empirically based algorithms or decision rules (e.g., “actual vs. expected” care) to 
define incomplete treatment. To our knowledge, no population-based study has attempted to 
adjudicate incomplete chemotherapy based on joint consideration of the (a) therapy 
recommended in the treatment plan, (b) course of treatment actually received, and (c) 
documented reasons for treatment discontinuation.
This article presents the first focused evaluation of both the receipt and the completion of 
adjuvant chemotherapy for breast cancer in a primarily rural region of the United States—
specifically, a 33-county area in the southwest portion of the state of Georgia (southwest 
Georgia— SWGA). Specifically, we examine (1) the extent to which early stage breast 
cancer patients in SWGA received adjuvant chemotherapy, and the factors associated with 
receipt of therapy; and (2) the extent to which patients who had a plan to start chemotherapy 
completed recommended treatment, and the factors associated with successful completion.
Of particular interest is whether the type of black–white differences found in urban and 
suburban populations of breast cancer patients are likewise evident in this largely rural 
region of the US.
Materials and methods
Patients and geographic setting
The study population included all women residing in SWGA1 diagnosed with a first 
primary, early stage breast cancer between January 1, 2001 and December 31, 2003, and 
who received at least their first 12 months of therapy post diagnosis entirely within the 
region. Incident breast cancer cases were identified through the Georgia Comprehensive 
Cancer Registry. Early stage breast cancer was defined to include diagnosis at American 
Joint Committee on Cancer (AJCC) stages I, II, or IIIA2. Receipt of neoadjuvant 
chemotherapy (prior to surgery) can impact decisions about the amount and timing of 
adjuvant chemotherapy, and may also have implications for the patient’s propensity to 
complete adjuvant therapies. Consequently, we excluded (as have others [7, 11]) those 
patients receiving neoadjuvant chemotherapy.
1The 33 counties comprising SWGA had a census-estimated population near the time of this study of about 724,000. About 82% of 
SWGA residents live in non-metropolitan areas. The median household income is about 72% of the U.S. average, and about 21% of 
the population lives below the Federal poverty line, compared with 12.4% nationally. About 38% of the population is African-
American [15].
2While characterizations of invasive “early stage” breast cancer vary in the literature, with some papers including only stages I and II, 
the definition here is consistent with current National Cancer Institute terminology (http://www.cancer.gov/dictionary?expand=E). 
Throughout, we combine stages IIA and IIB into a single stage II, given sample size constraints.
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Roughly 80–85% of cancer patients treated in SWGA receive care at one (or more) of four 
American College of Surgeons’ Commission on Cancer (CoC)-approved cancer centers3.
The study was approved by the institutional review boards at Emory University, the Centers 
for Disease Control and Prevention, and the Georgia Department of Community Health, and 
by committees at the four main cancer centers in SWGA.
Data collection and specification of variables
To meet study objectives, we developed a customized electronic data collection instrument 
and trained onsite abstractors to identify and code information from medical records. For 
each major type of cancer treatment, including chemotherapy, the electronic instrument 
guided the abstractor through a sequence of study-relevant inquiries on treatments planned, 
delivered, and discontinued. Data abstraction was conducted by five teams: one for each 
cancer center study site, and a fifth team assigned to 23 smaller hospitals and free-standing 
clinics operating across SWGA during the study period4.
While identifying patients who began adjuvant chemotherapy was relatively straightforward, 
determinating whether, when, and why a patient with a chemotherapy plan failed to 
complete treatment required a case-by-case examination. To proceed, all study-included 
cases were reviewed in detail by two of the authors (KCW and TWG), focusing on these two 
questions in the instrument: “Did the chemotherapy received match the plan?” and “If not, 
what were the reasons for not matching the plan?”. Each affirmative response (“Yes”) was 
validated by examining the recorded treatments given, their dates, and the overall degree of 
agreement between treatment plan and chemotherapy actually received. Each negative 
response (“No”) was evaluated similarly, but with additional assessment of the reason(s) 
recorded for not matching the planned care.
For our base-case analyses of chemotherapy completion, we excluded patients for whom the 
recorded reason for not matching planned care was death, from any cause. The 
discontinuation of cancer care in such cases was regarded as the (necessary) consequence of 
a change in treatment plan, rather than as a “discretionary” decision involving some 
assessment of the benefits and harms of continuing care. We tested the impact of this 
assumption through sensitivity analyses, as reported below.
Explanatory variables for analyses of both chemotherapy initiation and chemotherapy 
completion included age at diagnosis, race, marital status, insurance status, socio-economic 
status, rural status, comorbidity status, AJCC stage at diagnosis, estrogen receptor/
progesterone receptor (ER/PR) status, primary treatment site where care was received in 
SWGA, and the distance (in miles) between the patient’s residence and the primary 
3These study sites and their approximate total annual case volume (all cancer types) during the study period are as follows: Phoebe 
Cancer Center in Albany, 1,000–1,100; Pearlman Cancer Center at South Georgia Medical Center in Valdosta, 400–600; Singletary 
Oncology Center at Archbold Medical Center in Thomasville, 400–600; and Tift Regional Oncology Center at Tift Medical Center in 
Tifton, 300–400 [16]. During the study period, the nearest National Cancer Institute-designated cancer center was at least 180 miles 
away for virtually any SWGA resident.
4The Southwest Georgia Cancer Coalition, based in Albany, assisted Emory University investigators in developing effective working 
relationships with the four cancer centers. The fifth study team was managed by the GCCR Regional Coordinator for Southwest 
Georgia.
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treatment site. All variables were measured as of the time of breast cancer diagnosis, to the 
extent possible. Operational definitions are provided in Table 1.
Statistical analyses
For the two study outcomes of interest—receipt of adjuvant chemotherapy and successful 
completion of chemotherapy—we conducted univariate analyses with each of the 
explanatory variables, in turn, using χ2 tests accompanied by 2-sided p values. Guided by 
these findings, we estimated multivariable logistic regression models for each study 
outcome, with a focus on race and with the other explanatory variables regarded as potential 
con-founders. We tested for clinically and behaviorally plausible interaction effects. Logistic 
regression results were expressed as adjusted odds ratios, with corresponding 95% 
confidence intervals (CI). For the one predictor variable with a significant number of 
missing values, ER/PR status, we re-estimated the relevant model(s) omitting this variable, 
as a sensitivity analysis. To guard against overfitting the regressions, we adopted a 
commonly embraced guidepost5.
For patients who discontinued care prior to its scheduled completion we provide a 
descriptive summary of the reasons, as coded by the abstractors.
Analyses were conducted with SAS Version 9.2 (SAS Institute, Cary, NC).
Results
Of the 1,289 women diagnosed with breast cancer from January 1, 2001 through December 
31, 2003 in the 33-county region of SWGA, 1,096 (85%) were treated in SWGA (Fig. 1). Of 
these, 908 were diagnosed with early stage invasive disease. Excluding the 40 women who 
received neoadjuvant chemotherapy leaves 868 patients meeting study inclusion criteria.
Receipt of adjuvant chemotherapy
Overall, 344 of the 868 SWGA patients (39.6%) received adjuvant chemotherapy (Fig. 1).
In univariate analyses (Table 1), the percent of black women receiving chemotherapy was 
significantly greater than for whites (48.3 vs. 36.0%, p = 0.001). Receipt of chemotherapy 
was also positively and significantly associated with younger age at diagnosis, being 
married, having no comorbid conditions at time of diagnosis, later stage of diagnosis, and 
being ER/PR negative. There was a significant univariate insurance effect, with patients who 
had Medicaid or Medicaid/pending having the highest rate of chemotherapy use. Patients 
treated at CoC-approved hospitals had an overall higher prevalence of chemotherapy use 
than those treated at non-CoC facilities. In these unadjusted analyses, receipt of 
chemotherapy was positively (not inversely) related to distance from the patient’s home to 
her primary treatment facility.
5Specifically, we adhered to Harrell’s recommendation that for models with a binary response variable, the number of predictors 
should generally not exceed m/10, where m = min (N1, N2), and N1 and N2 are the marginal frequencies of the binary outcome [18].
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Our estimated base-case multivariable logistic regression model is reported in Table 2. After 
controlling for other demographic factors (e.g., age, marital status, insurance status), clinical 
factors (stage, ER/PR status, comorbidities), and provider factors (treatment site and the 
patient’s distance to it), there was no significant black– white difference in predicted receipt 
of chemotherapy. Receipt of chemotherapy was positively and significantly associated with 
younger age at diagnosis, a higher stage at diagnosis, and being ER/PR negative. Having 
Medicaid or Medicaid Pending was positively associated with receipt of chemotherapy, but 
no other insurance variable was significant. Patients living in a census tract with <10% of 
the population below the Federal poverty line were more likely to receive chemotherapy. 
The patient’s distance to the treatment site was not significant in this multivariable analysis, 
but site-of-care remained a significant predictor of receiving chemotherapy6.
While ER/PR status was an important predictor of receiving chemotherapy, observations on 
this variable were missing for 131 of our 868 patients (Table 1). In a sensitivity analysis (not 
shown), we re-estimated the logistic regression model excluding ER/PR status, thereby 
increasing the available sample from 721 to 846. There were no changes in sign or patterns 
of statistical significance for the remaining variables in the model.
In additional multivariable modeling (not shown), we found no significant interaction effects 
between race and the other predictor variables.
The model in Table 2 and its variants exhibited high goodness-of-fit, with a c index 
(probability of concordance) of 0.907 in the base case and above 0.886 in all variants.
Completion of planned adjuvant chemotherapy
In addition to the 344 patients who began chemotherapy, three additional patients had a 
treatment plan but did not start (Fig. 1). Of these 347 patients, 310 (89.3%) completed 
planned chemotherapy, so that 37 (10.7%) did not.
We note in passing that of the 310 patients who completed planned adjuvant chemotherapy, 
270 had no recorded change in plan; the 40 who did included also the four patients who died 
during the initial treatment period.
In univariate analyses (Table 3), the percentage of patients completing planned 
chemotherapy was higher for blacks than whites (92.0 vs. 87.8%), but the difference was not 
statistically significant (p = 0.227). There was an age effect, with patients under age 65 
completing chemotherapy at a higher rate, but no other significant effects.
6Because the patient’s distance from her home to primary site of treatment may be regarded as an important attribute of the site itself, 
we estimated alternative versions of the model that excluded, in turn, the distance variables and the site-of-care variables. The results 
(available from the authors upon request) confirmed the robustness of the model reported in Table 2. The site-of-care variables 
remained significant when distance was omitted; the distance variables remained insignificant when the site-of-care variables were 
omitted; and the statistical performance of the other variables in these model variants were consistent with the results in Table 2. The 
persistence of this site-of-care effect, after controlling for multiple patient-level factors, is noteworthy and suggests that the style of 
medical oncology practice may have differed systematically across these CoC-approved cancer centers during the 2001–2003. 
However, the fact that only four cancer centers (plus 23 smaller hospitals) are involved inherently limits our ability to generalize about 
site effects.
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While the sample size limited the number of variables that could be simultaneously included 
in a multivariable regression model here, we did identify robust interaction effects involving 
race, the presence of comorbid conditions, and marital status (Table 4).
In the direct-effects specification (Table 4, Model 1), the adjusted black–white odds ratio for 
completing planned chemotherapy was 2.36 [p = 0.052, CI (0.99–5.62)], while the odds ratio 
associated with 1 or more comorbid conditions, 0.53, trended toward significance [p = 
0.085, CI (0.26–1.09)], controlling for marital status. Additional insight into how marital 
status appears to mediate the impact of both race and comorbidity status on the likelihood of 
completing chemotherapy is revealed in Model 2, where race and comorbidity status are 
each interacted with marital status. Conditional on being unmarried, the black:white odds 
ratio for completing planned therapy was 4.67 and highly significant [CI (1.36–16.04)]7. 
Similarly, conditional on being unmarried, patients with 1 or more comorbidities were 
significantly less likely to complete planned therapy. For married patients, there was no race 
or comorbidity effect on the likelihood of completing chemotherapy.
In additional regressions not reported here, the overall trends concerning the impact of race, 
comorbidity, and marital status on the likelihood of completing chemotherapy were not 
affected when additional candidate predictors were included in the model, either singly or in 
combination (e.g., age, insurance status, socioeconomic status). Good-ness-of-fit for the 
regressions in Table 4 was only modest (c = 0.627 and 0.676), reflecting in part our 
adherence to guidelines against overfitting.
Finally, recall that patients who died while still undergoing adjuvant chemotherapy were not 
counted in the group that “discontinued” planned care. This is consistent with Ramsey et al. 
[19], though other analyses have not made death during the period of adjuvant therapy an 
exclusion criterion [8, 9]. To investigate the robustness of our base-case results, we re-
assigned the four patients who stopped adjuvant chemotherapy because of death to the group 
classified as having not completed planned chemotherapy. This increased the total who 
failed to complete planned therapy from 37 to 41 (see Fig. 1 note), and the corresponding 
percent who failed to complete from 10.7 to 11.8% (41/347 × 100). We then repeated all 
univariate and multivariable analyses related to completion of chemotherapy. The results 
(available upon request) were virtually unchanged from the base-case findings reported in 
Tables 3 and 4 in terms of the algebraic sign and statistical significance of individual 
variable effects.
Reasons for early termination of planned adjuvant chemotherapy
For each of the 37 patients not completing planned chemotherapy in the base case, we 
assigned a primary reason based on the abstracted medical records. The results are noted in 
Fig. 1 and summarized in Fig. 2. About two-thirds of these patients failed to complete 
chemotherapy for clinical reasons (toxicity, 54%; disease progression, 3%; and other clinical 
reasons, 8%). The remaining one-third did not complete for “other patient-related reasons” 
7For logistic models with interaction terms, SAS 9.2 computes a 95% confidence interval for the odds ratio for the variable of interest 
in the interaction term (e.g., race), conditional on the assumed value of the other variable in the (two-way) interaction term (e.g., 
marital status), rather than p values for the individual direct effect and interaction terms included in the regression. See note c in Table 
4.
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(patient decision to stop, 16%; started, then no show, 5%; other patient reasons, 6%; and had 
plan but did not start, 8%). Of note, 16 of 27 (59%) white patients and 8 of 10 (80%) black 
patients stopped care for clinical reasons, though in this modest-size sample, the difference 
by race across the seven defined primary reasons for termination was not significant (p = 
0.694)8.
Discussion
Given the important findings by Hershman et al. [8] that among breast cancer patients in a 
large urban–suburban population and in randomized trials [9], blacks were significantly less 
likely than whites to complete adjuvant chemotherapy, we asked whether there were similar 
racial differences in SWGA. What we found was strikingly different:
• Regarding receipt of chemotherapy, the unadjusted difference between blacks and 
whites was highly significant (Table 1); but in the multivariable analysis (Table 2), 
the black–white odds ratio was not. The latter finding of no significant difference is 
consistent with multivariable modeling results reported by Elkin et al. [6] in a 
SEER-Medicare sample, Kimmick et al. [20] among North Carolina Medicaid 
enrollees, and Lund et al. [12] in Metropolitan Atlanta. However, in another 
multivariable analysis using SEER-Medicare data, Giordano et al. [7] found that 
white breast cancer patients were significantly more likely than black patients to 
receive chemotherapy, as did Bickell et al. [10] in their New York City study and, 
most recently, Freedman et al. [21] in a National Cancer Data Base Study (which 
did not distinguish patients by urban/rural status). These studies controlled for 
many of the same key factors, e.g., stage, ER/PR status, as did our analyses. But 
they also differed (from our work and among each other) in terms of population 
studied and data resources, time period examined, and statistical modeling 
approaches. Future work to sort out these contrasting findings will need to account 
for differences in data and methods.
• While the difference between blacks and whites in completing chemotherapy was 
not significant in a univariate analysis (Table 3), black race was positively 
associated with completing care in multivariable models (Table 4). Moreover, the 
impact of race on completing chemotherapy appears to be influenced by the 
patient’s marital status—with a significant black– white difference for patients who 
are not married patients, but no difference for those married. This interplay 
between marital status and race (and also marital status and comorbidity status) on 
patterns of care in cancer has not been previously reported, to our knowledge, and 
merits further investigation.
• The overall rate of premature discontinuation of chemotherapy for breast cancer in 
SWGA was 10.7%. This is similar to the Hershman et al. [9] calculation of 9% 
based on a synthesis of clinical trials data, and to the estimate of 13.5% by Buist et 
al. [22] based on data from several large HMOs. These estimates contrast sharply 
8When the 7 primary reasons for termination were collapsed into clinical reasons (3) and other patient-related reasons (4), there was 
still no significant black-white difference (p = 0.241, using Pearson’s exact test, and p = 0.432 after application of the Yates correction 
for small expected cell sizes).
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with the 28% figure reported for the Metropolitan Detroit area [8]. Both Hershman 
et al. analyses define discontinuation by comparing actual care with guideline-
driven expected care, while Buist et al. rely on medical chart abstraction and 
physician notes, similar to the approach taken in this study.
Strengths, limitations, and matters for further investigation
This article provides the most comprehensive examination to date of factors associated with 
receipt and successful completion of adjuvant chemotherapy for breast cancer in a primarily 
rural region of the U.S. The analyses draw from virtually a complete census of patients 
diagnosed and treated for early stage breast cancer in the 33-county area of SWGA over the 
3-year period 2001–2003.
However, the study has some important limitations. First, it focuses on one particular 
geographic area. It remains to be seen whether similar findings would emerge in other rural 
regions, particularly in other parts of the country. Over 80% of the cancer care in SWGA is 
rendered at four CoC-approved cancer centers, which are expected to promote evidenced-
based multidisciplinary care. Rural regions with a smaller percentage of breast cancer care at 
CoC-approved facilities could yield different findings. Second, our results necessarily reflect 
the patterns of care for breast cancer cases diagnosed in SWGA during 2001–2003, thus, 
raising questions about generalizability over time. However, we are unaware of changes in 
breast cancer treatment guidelines or third-party reimbursement policies over the past 
decade that would have significantly altered the environment for decision making about 
adjuvant chemotherapy for breast cancer.
A third and more fundamental limitation of our analyses, and the others discussed here, is 
the absence of the patient’s own perspective on the decision to begin or to discontinue 
therapy, including the impact of treatment (actual or anticipated) on health-related quality of 
life [23]. This severely limits our ability ex post facto to develop a satisfactory explanation 
for these black–white differences (or the lack thereof) and for the evident interplay between 
marital status, race, and completion of therapy.
Regarding the effect of race on receipt and completion of care, our discussions (in 2009) 
with providers and administrators at the 4 cancer centers in SWGA pointed to two general 
considerations. First, during 2001–2003 (and subsequently) each center provided free 
transportation services to patients who petitioned for help; and each was a federally 
designated “disproportionate share” hospital— implying that admission and treatment 
decisions were not to be influenced by the patient’s ability to pay. It is possible these center-
specific factors served to attenuate race-based differences in patterns of care. Second, to the 
extent that social support networks that are anchored through churches and extended 
families are more extensively developed in the black community, this could influence the 
propensity to undergo and stay the course with cancer therapy.
In a similar vein, it is conceivable that the patients who were unmarried (and among those in 
Table 3, this includes 59.8% of blacks compared to 29.0% of whites) and had strong ties 
within such a network thereby had a “social support” advantage over unmarried patients 
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with fewer social ties. If so, this could shed light on the race-marital status interaction effect 
on the propensity to complete adjuvant chemotherapy.
Regarding matters for further investigation, the first follows directly from above: the need 
for patient-reported information that can help identify the full set of factors influencing the 
patient’s treatment decisions. Second, our findings on the impact of health insurance are 
generally contrary to expectations [24]. Women with Medicaid/ Medicaid Pending were 
more likely to receive chemotherapy compared with the privately insured, and there were no 
other significant insurance effects. Although it is not clear why the impact of insurance is 
relatively muted here, the strong Medicaid effect may be explained, in part, by the launch of 
the CDC’s Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) program 
in July 2001. Georgia was one of 12 states adopting the most expansive BCCPTA 
enrollment option, which resulted in a significant increase in the Medicaid enrollment rate 
for women diagnosed with breast cancer [25]9.
Third, a centrally important matter is the impact of failing to complete chemotherapy on 
survival. Most patients in our analyses received multi-modality care, including radiation 
therapy or hormonal therapy, in additional to adjuvant chemotherapy, following surgery. A 
survival analysis that accounts for the joint impact of these treatment modalities—while 
adjusting for patient, provider, and health system factors [26]—is an important next step but 
beyond the scope of this article.
As Hassett and Griggs [27] note, the assessment of racial disparities in adjuvant 
chemotherapy for breast cancer has come to focus increasingly on black–white differences 
not only the receipt of care, but its timely and dose-appropriate delivery—and its successful 
completion. This article contributes to that expanding discussion by asking whether the 
differences by race found in previous US studies likewise surface when the geographic focus 
shifts to a primarily rural region of the country. On balance, we find compelling black–white 
differences—but with black patients receiving and completing care at rates that equal or 
exceed those for white patients. Further investigation is warranted, both in SWGA and other 
rural areas of the US.
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Table 1
Receipt of adjuvant chemotherapy, by demographic and clinical characteristics, among women with early 











Age at diagnosis (years)
  <50 177 20.3 72.3 <0.0001
  50–64 323 37.2 49.2
  65–74 167 19.2 29.9
  75+ 201 23.1 3.5
Racea
  White 611 70.4 36.0 0.001
  Black 257 29.6 48.3
Marital statusb
  Married 439 51.2 46.7 <0.0001
  Not married 418 48.8 32.3
Insurance statusc
    Private (FFS,
HMO) + Medicare
606 70.0 38.8 <0.0001





    Medicaid or
Medicaid Pending
78 9.0 69.2
    Uninsured (self-
Pay/charity)
62 7.1 41.9
Socioeconomic status: % in census tract below poverty leveld
  >20 443 51.7 38.8 0.447
  10–20 292 34.1 39.3
  <10 122 14.2 45.1
Rural status (%)e
  Metro 162 18.7 44.4 0.165
  Non-metro 706 81.3 38.5
Comorbid conditionsf
  None 451 52.0 44.1 0.005
  1 or more 417 48.0 34.8
AJCC stage at diagnosis
  I 445 51.2 19.8 <0.0001
  II 327 37.7 59.3
  IIIA 96 11.1 64.6
Estrogen/progesterone statusg
























  ER- and PR- 167 22.7 64.7 <0.0001
  ER+ or PR+ 570 77.3 36.5
Treatment siteh
  A 47.7 <0.0001
  B 45.4
  C 34.5
  D 29.7
  Other 21.2
Distance to treatment site (miles)i
  <5 293 33.8 34.1 0.025
  5–22 292 33.6 39.7
  >22 283 32.6 45.2
Early stage invasive refers to breast cancer diagnosed at AJCC stages I, IIA, IIB, or IIIA, and aligns with the National Cancer Institute’s definition 
of “early stage” breast cancer (see http://www.cancer.gov/dictionary?expand=E)
a
Defined as 2-level variable that includes non-Hispanic whites (White) and non-Hispanic blacks (Black), since all other racial/ethnic groups, 
including Hispanics, together constituted only 0.8% of the incident breast cancer cases in SWGA in 2001–2003
b
Not married includes women who are single, separated, divorced, or widowed
c
This 4-level variable was constructed from the coverage options in a drop-down box in the electronic data collection instrument as follows: 
uninsured (no insurance, self-pay, or charity); Medicaid (either enrolled in Medicaid or application for enrollment pending); Medicare only 
(enrolled in fee-for-service Medicare and without supplemental private insurance); and private insurance/managed care (private insurance, health 
maintenance organization/independent practice association (HMO/IPA), Medicare advantage or fee-for-service Medicare with supplemental private 
insurance, and CHAMPUS or VA coverage). The inclusion of military service-related options in the final category assumes that cancer care 
provided by the Department of Defense and the Department of Veterans Affairs is delivered in a “managed care” type of environment. 
Consistently, the intent was to capture insurance status at time of diagnosis, to the extent possible
d
Based on whether the patient’s residential address lies in a US census tract where greater than 20%, between 10 and 20%, or fewer than 10% of 
the population is classified as living below the Federal poverty line in 2000
e
To index the degree of rurality (Rural Status) associated with the patient’s residential address, she was designated as metro if she lived in a county 
that met any of the Beale Code’s 3 conditions for being a “metro county”; otherwise, she was assigned non-metro status. The formulas and 
rationale for the Beale Code classification of urban/rural status are provided by the US Department of Agriculture [17]
f
As coded at the time of diagnosis, based on the following menu of options built into the project’s electronic data reporting instrument: myocardial 
infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, 
ulcer disease, dementia, hemiplegia, AIDS, diabetes, diabetes with end organ damage, mild liver disease, moderate/severe liver disease, moderate/
severe renal disease, any tumor, leukemia, lymphoma, metastatic solid tumor (Note also that any patient with a recorded previous cancer was 
excluded from these analyses)
g
Hence, patients are classified as double-negative versus ER positive or PR positive or both
h
Sites of care A–D are the four CoC-approved hospitals in SWGA, while other indicates the patient received her cancer care primarily at some 
other treatment facility in SWGA
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Table 2




Age at diagnosis (years)
  <50 1.000
  50–64 0.297 0.167–0.529 <0.0001
  65–74 0.124 0.060–0.257 <0.0001
  75+ 0.006 0.002–0.016 <0.0001
Race
  White 1.000
  Black 1.178 0.712–1.948 0.524
Marital status
  Married 1.000
  Not married 0.693 0.427–1.125 0.138
Insurance status




    Medicare Only (no
supplemental)
1.310 0.639–2.685 0.462
    Medicaid or Medicaid
Pending
3.176 1.407–7.170 0.005
  Uninsured (self-pay/charity) 0.741 0.315–1.741 0.491
Census tract % below poverty level
  >20 1.000
  10–20 1.326 0.802–2.192 0.271
  <10 2.078 1.009–4.277 0.047
Rural status
  Metro 1.000
  Non-metro 1.194 0.547–2.606 0.657
Comorbid conditions
  None 1.000
  1 or more 1.293 0.809–2.065 0.283
AJCC stage at diagnosis
  I 1.000
  II 12.961 7.983–21.043 <0.0001
  IIIA 25.135 10.474–60.318 <0.0001
Estrogen/progesterone status
  ER− and PR− 1.000
  ER+ or PR+ 0.388 0.228–0.661 0.001
Treatment site
  A 1.000
  B 0.692 0.321–1.493 0.349

















  C 0.410 0.191–0.878 0.022
  D 0.268 0.117–0.611 0.002
  Other 0.400 0.157–1.015 0.054
Distance to treatment site (miles)
  <5 1.000
  5–22 0.846 0.482–1.485 0.560
  >22 1.125 0.561–2.257 0.740
N = 721; c index (probability of concordance) = 0.907
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Table 3
Completion of planned adjuvant chemotherapy, by demographic and clinical characteristics
Characteristic No. of patients who began
or had Tx plan for adj
chemo (N = 347)
No. of patients (%) who
completed adj
chemo (N = 310)
χ2p
Age at diagnosis (years)
  <50 128 115 (89.8) 0.012
  50–64 160 149 (93.1)
  65–74 52 40 (76.9)
  75+ 7 6 (85.7)
Race
  White 222 195 (87.8) 0.227
  Black 125 115 (92.0)
Marital Status
  Married 206 188 (91.3) 0.372
  Not married 137 121 (88.3)
Insurance status
  Private (FFS, HMO) + Medicare
w/supplemental + VA/CHAMPUS
238 213 (89.5) 0.906
  Medicare Only (no supplemental) 29 25 (86.2)
  Medicaid or Medicaid Pending 54 48 (88.9)
  Uninsured (self-pay/charity) 26 24 (92.3)
Census tract % poverty
  >20 175 153 (87.4) 0.278
  10–20 115 107 (93.0)
  <10 55 48 (87.3)
Rural status (%)
  Metro 73 65 (89.0) 0.927
  Non-metro 274 245 (89.4)
Comorbid conditions
  None 199 182 (91.5) 0.138
  1 or more 148 128 (86.5)
AJCC stage at diagnosis
  I 89 77 (86.5) 0.387
  II 196 175 (89.3)
  IIIA 62 58 (93.5)
Estrogen/progesterone status
  ER− and PR− 108 97 (89.8) 0.748
  ER+ or PR+ 211 187 (88.6)
Treatment site
  A (87.5) 0.124
  B (93.7)
  C (83.3)
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Characteristic No. of patients who began
or had Tx plan for adj
chemo (N = 347)
No. of patients (%) who
completed adj
chemo (N = 310)
χ2p
  D (100.0)
  Other (88.0)
Distance to treatment site (miles)
  <5 101 94 (93.1) 0.151
  5–22 116 105 (90.5)
  >22 130 111 (85.4)
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